🇺🇸 PTCT — PTC Therapeutics, Inc.

Salud Compra
← Volver

Precio actual

68,12 USD

Máx. histórico

89,55

117 días

Caída desde máximo

-23,93%

Rango 52 semanas

58,80 – 90,87

Variación hoy

+11,89%

Cierre anterior

60,88

Rango de hoy

63,16 – 68,72

Volumen hoy

2.643.738

Peor caída histórica

-94,60%

17/03/2015 → 03/11/2016

Recuperado en 3305 días

Volatilidad anualizada ⓘ

72,99%

Información
Nombre completo
PTC Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
991
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
100,47 USD (puede no estar actualizado)
Primera cotización
20/06/2013
Precio actualizado
hace 11 horas
Sobre la empresa

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
21/10/2024 38,75 39,25 37,65 38,44 -1,69% 4,13% 515.400
18/10/2024 37,02 39,58 36,82 39,10 +5,65% 7,44% 572.100
17/10/2024 36,63 37,26 35,51 37,01 +0,84% 4,78% 1.100.700
16/10/2024 37,76 37,85 36,66 36,70 -2,29% 3,15% 667.200
15/10/2024 39,00 39,05 37,51 37,56 -4,04% 3,94% 852.800
14/10/2024 38,51 39,74 38,51 39,14 +0,36% 3,19% 734.000
11/10/2024 38,48 39,22 38,29 39,00 +1,33% 2,42% 810.600
10/10/2024 38,71 39,45 38,05 38,49 -3,63% 3,62% 838.800
09/10/2024 40,71 41,00 39,12 39,94 -2,04% 4,62% 1.187.000
08/10/2024 35,50 41,81 35,14 40,77 +16,52% 18,79% 2.188.400
07/10/2024 35,03 35,63 34,57 34,99 -0,31% 3,03% 379.800
04/10/2024 35,87 36,28 34,77 35,10 -0,76% 4,21% 287.600
03/10/2024 35,97 36,32 34,65 35,37 -2,91% 4,64% 544.700
02/10/2024 35,95 37,36 35,91 36,43 +1,05% 4,03% 736.800
01/10/2024 37,00 37,57 35,80 36,05 -2,83% 4,78% 1.238.900
30/09/2024 37,50 37,87 36,83 37,10 -1,22% 2,79% 1.156.900
27/09/2024 38,06 38,06 37,23 37,56 -0,27% 2,18% 1.084.200
26/09/2024 36,84 38,62 36,45 37,66 +2,78% 5,89% 1.161.600
25/09/2024 36,71 37,22 36,35 36,64 +0,33% 2,37% 446.000
24/09/2024 36,93 36,97 36,26 36,52 -0,63% 1,92% 551.600
23/09/2024 36,76 37,31 36,29 36,75 +0,30% 2,77% 490.300
20/09/2024 36,20 37,17 35,22 36,64 +1,33% 5,37% 1.153.900
19/09/2024 36,36 37,09 35,94 36,16 +1,92% 3,16% 530.800
18/09/2024 35,12 36,90 34,68 35,48 +1,17% 6,34% 608.900
17/09/2024 34,00 35,11 33,88 35,07 +3,85% 3,62% 563.900
16/09/2024 34,18 34,22 33,58 33,77 -0,65% 1,89% 595.900
13/09/2024 33,19 34,89 33,19 33,99 +3,94% 5,12% 395.600
12/09/2024 32,25 33,27 31,80 32,70 +1,33% 4,56% 524.500
11/09/2024 31,63 32,48 30,98 32,27 +2,31% 4,74% 675.800
10/09/2024 31,38 32,11 31,13 31,54 +0,38% 3,12% 445.200